Phase II Study of the Pathophysiology and Treatment With Enalapril and Polystyrene Sulfonate for Pseudohypoaldosteronism, Type I
Completed
University of Texas
Phase 2
1992-12-01
OBJECTIVES: I. Establish the sodium and potassium intake that will maintain a normovolemic
state in a patient with pseudohypoaldosteronism.
II. Determine the effect of extracellular fluid volume and serum potassium manipulations on
exercise tolerance, cardiac function, and endurance.
III. Investigate pharmacologic methods of limiting excretion of sodium in urine and sweat.
Phase II Study of the Pathophysiology and Treatment With Enalapril and Polystyrene Sulfonate for Pseudohypoaldosteronism, Type I
Completed
National Center for Research Resources (NCRR)
Phase 2
1992-12-01
OBJECTIVES: I. Establish the sodium and potassium intake that will maintain a normovolemic
state in a patient with pseudohypoaldosteronism.
II. Determine the effect of extracellular fluid volume and serum potassium manipulations on
exercise tolerance, cardiac function, and endurance.
III. Investigate pharmacologic methods of limiting excretion of sodium in urine and sweat.
Levothyroxine (L-T4) Absorption After Bariatric Surgery
Completed
University of Sao Paulo
N/A
2007-09-01
Intestinal absorption of levothyroxine (LT4) tablets depends on its dissolution in gastric
acid secretion, which is reduced after bariatric interventions. Impaired LT4 absorption due
to low gastric dissolution has been reported in patients with atrophic or chronic gastritis.
The objective of this study is to evaluate the absorption of LT4 tablets in morbidly obese
patients before and after Roux-en-Y bariatric surgery.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
